CABOMETYX®
Resources for Healthcare Professionals
Click for Resources
Renal Cell Carcinoma (RCC)
CABOMETYX® (cabozantinib) is indicated for the treatment of advanced renal cell carcinoma (RCC) in treatment-naïve adults with intermediate or poor risk, and in adult patients who have received prior therapy.
CABOMETYX®, in combination with nivolumab, is indicated for the first-line treatment of adult patients with advanced (not amenable to curative surgery or radiation therapy) or metastatic renal cell carcinoma (RCC).
Hepatocellular Carcinoma (HCC)
CABOMETYX® is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.
Differentiated Thyroid Carcinoma (DTC)
CABOMETYX® is indicated for the treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma (DTC) that has progressed following prior VEGFR-targeted therapy and who are radioactive iodine-refractory or ineligible.
Click on a resource below to access it on your computer or mobile device. If you require printed copies, please contact your CABOMETYX® Representative.
Resources
For more information:
Consult the Product Monograph at health-products.canada.ca/dpd-bdpp/ for important information relating to adverse reactions, drug interactions and dosing information. The Product Monograph is also available by calling IPSEN Medical Information at 1-855-215-2288 or by emailing medinfo.canada@ipsen.com.